Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of New Adalimumab Formulation in RA
NCT01752855Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2012
- Primary completion
- Oct 2013
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of adalimumab in rheumatoid arthritis (RA), sponsored by AbbVie Inc.. Started Dec 2012; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01752855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01752855.